IPO registrations (S-1, F-1) · Registrants
Prevail Therapeutics Inc.
- SEC CIK
- 1714798 · filings on EDGAR ↗
- Registration
- Form S-1, first filed 2019-05-24, last 2019-06-10; 1 initial registration, 1 amendment
- Outcome
- Final prospectus filed 2019-06-20; declared effective 2019-06-19
- Industry (SIC)
- Biological Products, (No Diagnostic Substances) 2836
- Incorporated in
- DE
- Business address
- 430 EAST 29TH STREET, SUITE 940, New York, NY 10016
- EDGAR entity type
- operating
- Insiders and CEO pay
- Prevail Therapeutics Inc. on the corporate pages
Offering terms
- Proposed price range
- $16.00–$18.00 per share (S-1/A filed 2019-06-10)
- Final price
- $17.00 per share, within the range (424B4 filed 2019-06-20, an initial public offering)
- Shares sold
- 7,353,000
- Gross proceeds
- $125,001,000 before underwriting discounts and any over-allotment option
- Listing
- Nasdaq under the symbol PRVL
- Lead underwriters
- Morgan Stanley; BofA Securities; Cowen
- Syndicate
- Wedbush Securities; BALANCE SHEETS December 31, March 31 (2,019)
Read from the cover pages of the filings listed under “Prospectus pages read” below; check the document for anything that matters.
On this site
- Business registration: PREVAIL THERAPEUTICS INC. Fuzzy (name and state)
- Form D issuer: Prevail Therapeutics Inc. EXACT (CIK (EXACT))
- SEC filer: Prevail Therapeutics Inc. EXACT (CIK (EXACT))
Filings 6
| Filed | Form | What it is | Name as filed | EDGAR |
|---|---|---|---|---|
| 2019-05-24 | S-1 | S-1 (registration) | Prevail Therapeutics Inc. | 0001193125-19-157078 ↗ |
| 2019-06-10 | S-1/A | S-1/A (amendment) | Prevail Therapeutics Inc. | 0001193125-19-168749 ↗ |
| 2019-06-19 | EFFECT | EFFECT (declared effective) | Prevail Therapeutics Inc. | 9999999995-19-001379 ↗ |
| 2019-06-20 | 424B4 | 424B4 (final prospectus) | Prevail Therapeutics Inc. | 0001193125-19-177602 ↗ |
| 2020-07-08 | EFFECT | EFFECT (declared effective) | Prevail Therapeutics Inc. | 9999999995-20-001719 ↗ |
| 2021-01-26 | EFFECT | EFFECT (declared effective) | Prevail Therapeutics Inc. | 9999999995-21-000278 ↗ |
Prospectus pages read 2
| Filed | Form | Read as | Range | Price | Shares | Proceeds | Listing | Underwriters | What was found | Document |
|---|---|---|---|---|---|---|---|---|---|---|
| 2019-06-10 | S-1/A | registration statement | $16.00–$18.00 | 7,353,000 | - | Nasdaq PRVL | 5 | primary document; range, shares headline, underwriting table 1, cover names 4 | document ↗ | |
| 2019-06-20 | 424B4 | final prospectus | $17.00 | 7,353,000 | $125,001,000 | Nasdaq PRVL | 5 | primary document; price sentence, shares headline, proceeds table, underwriting table 1, cover names 4 | document ↗ |
Officers, directors and large holders Forms 3, 4 and 5
| Insider | Role | Title | Filings | Years | On this site |
|---|---|---|---|---|---|
| Abeliovich Asa | Director,Officer; Director,Officer,TenPercentOwner | President & CEO | 4 | 2019–2021 | |
| Adams Timothy M | Director | 3 | 2019–2021 | ||
| Dai Yong | Officer | Chief Technology Officer | 3 | 2019–2021 | |
| GORDON CARL L | Director,TenPercentOwner | 4 | 2019–2021 | ||
| Hefti Franz | Officer | Chief Development Officer | 3 | 2019–2021 | |
| Kaplan Brett | Officer | Chief Financial Officer | 3 | 2019–2021 | |
| Minkow Emily | Officer | Chief Business Officer | 4 | 2019–2021 | |
| Nader Francois | Director | 4 | 2019–2021 | ||
| Nussbaum Ran | Director | 3 | 2019–2021 | ||
| ORBIMED ADVISORS LLC | Director,TenPercentOwner | 3 | 2019–2021 | ||
| OrbiMed Capital GP VI LLC | Director,TenPercentOwner | 3 | 2019–2021 | ||
| Sevigny Jeffrey | Officer | Chief Medical Officer | 3 | 2019–2021 | |
| Thompson Peter A. | Director,TenPercentOwner | 4 | 2019–2021 | ||
| Sheng Morgan | Director | 4 | 2019–2021 | ||
| Schwartz Kira M. | Officer | General Counsel | 3 | 2020–2021 | |
| Carson William H. | Director | 3 | 2020–2021 | ||
| ELI LILLY & Co | TenPercentOwner | 2 | 2020–2021 | ||
| Tyto Acquisition Corp | TenPercentOwner | 2 | 2020–2021 |
Everyone who filed an insider report for this company, from the SEC’s Insider Transactions Data Sets (2006 on). Person pages are matched by name and state only.
Private offerings before or after (Form D)
| First filed | Issuer | Industry | Offering | Sold | Investors | Filings |
|---|---|---|---|---|---|---|
| 2018-03-14 | Prevail Therapeutics Inc. | Other Health Care | $65,000,059 | $57,000,049 | 15 | 1 |
Data: SEC EDGAR. The quarterly full index (every S-1, S-1/A, F-1 and F-1/A since 1993, with the pricing prospectus, notice of effectiveness and withdrawal request of each registrant) and the company submissions data (SIC, state of incorporation, address, EIN, tickers, former names). Company details are what EDGAR holds today, not at the time of the filing.
Also on this site Fuzzy
| Record | Name as filed | Where | Dataset | Matched by |
|---|---|---|---|---|
| Business registration | PREVAIL THERAPEUTICS INC. | NY | State business registries | name and state |
| Form D issuer | Prevail Therapeutics Inc. | NY | Form D private offerings | CIK (EXACT) |
| Patent assignee | Prevail Therapeutics, Inc. | NY | Patents (USPTO) | name and state |
| SEC filer | Prevail Therapeutics Inc. | SEC filers (EDGAR) | CIK (EXACT) | |
| Trademark owner | Prevail Therapeutics, Inc. | NY | Trademarks (USPTO) | name and state |
Matched by an identifier (EIN, CIK, CRD), by name and state or city, or by street address; a shared name or address is not proof of the same person or organization. Every link says how it was made; how the cross-referencing works.
Others with the same interests
SIC industry Biological Products, (No Diagnostic Substances), NY first:
- Acorda Therapeutics, Inc. NY
- BRAINSTORM CELL THERAPEUTICS INC. NY
- ANAVEX LIFE SCIENCES CORP. NY
- CytRx Oncology Corp NY
- Omrix Biopharmaceuticals, Inc. NY
- Protara Therapeutics, Inc. NY
- COGNITION THERAPEUTICS INC NY
- Bavarian Nordic A/S / ADR NY
- Qrons Inc. NY
- MeiraGTx Holdings plc NY
In other datasets, the same topic (Health) in NY:
- Nonprofit: AABR FOUNDATION INC (Nonprofits (IRS Form 990))
Interests: Biological Products, (No Diagnostic Substances) · Health